{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,4,7]],"date-time":"2025-04-07T13:22:58Z","timestamp":1744032178375},"reference-count":24,"publisher":"Oxford University Press (OUP)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2005,10,1]]},"DOI":"10.1093\/jac\/dki284","type":"journal-article","created":{"date-parts":[[2005,8,25]],"date-time":"2005-08-25T00:13:23Z","timestamp":1124928803000},"page":"703-708","source":"Crossref","is-referenced-by-count":19,"title":["Plasma concentrations might lead to overestimation of target site activity of piperacillin in patients with sepsis"],"prefix":"10.1093","volume":"56","author":[{"given":"M. A.","family":"Zeitlinger","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B. M.","family":"Erovic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Sauermann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Georgopoulos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"M\u00fcller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Joukhadar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2005,8,24]]},"reference":[{"key":"key\n\t\t\t\t20171010173126_B1","doi-asserted-by":"crossref","unstructured":"Ryan DM. Pharmacokinetics of antibiotics in natural and experimental superficial compartments in animals and humans. J Antimicrob Chemother1993; 31 Suppl D: 1\u201316.","DOI":"10.1093\/jac\/31.suppl_D.1"},{"key":"key\n\t\t\t\t20171010173126_B2","doi-asserted-by":"crossref","unstructured":"Joukhadar C, Klein N, Dittrich P et al. Target site penetration of fosfomycin in critically ill patients. J Antimicrob Chemother2003; 51: 1247\u201352.","DOI":"10.1093\/jac\/dkg187"},{"key":"key\n\t\t\t\t20171010173126_B3","doi-asserted-by":"crossref","unstructured":"Zeitlinger MA, Dehghanyar P, Mayer BX et al. Relevance of soft-tissue penetration by levofloxacin for target site bacterial killing in patients with sepsis. Antimicrob Agents Chemother2003; 47: 3548\u201353.","DOI":"10.1128\/AAC.47.11.3548-3553.2003"},{"key":"key\n\t\t\t\t20171010173126_B4","unstructured":"EMEA. Points to Consider on Pharmacokinetics and Pharmacodynamics in the Development of Antibacterial Medicinal Products, 2000. http:\/\/www.emea.eu.int\/pdfs\/human\/ewp\/265599en.pdf (10 July 2005, date last accessed)."},{"key":"key\n\t\t\t\t20171010173126_B5","unstructured":"FDA. Guidance for Industry. Developing Antimicrobial Drugs\u2014General Considerations for Clinical Trials, 1998. http:\/\/www.fda.gov\/cder\/guidance\/2580dft.pdf (10 July 2005, date last accessed)."},{"key":"key\n\t\t\t\t20171010173126_B6","doi-asserted-by":"crossref","unstructured":"Joukhadar C, Frossard M, Mayer BX et al. Impaired target site penetration of \u03b2-lactams may account for therapeutic failure in patients with septic shock. Crit Care Med2001; 29: 385\u201391.","DOI":"10.1097\/00003246-200102000-00030"},{"key":"key\n\t\t\t\t20171010173126_B7","doi-asserted-by":"crossref","unstructured":"Herkner H, Muller MR, Kreischitz N et al. Closed-chest microdialysis to measure antibiotic penetration into human lung tissue. Am J Respir Crit Care Med2002; 165: 273\u20136.","DOI":"10.1164\/ajrccm.165.2.2106082"},{"key":"key\n\t\t\t\t20171010173126_B8","doi-asserted-by":"crossref","unstructured":"Brunner M, Pernerstorfer T, Mayer BX et al. Surgery and intensive care procedures affect the target site distribution of piperacillin. Crit Care Med2000; 28: 1754\u20139.","DOI":"10.1097\/00003246-200006000-00009"},{"key":"key\n\t\t\t\t20171010173126_B9","doi-asserted-by":"crossref","unstructured":"Brunner M, Hollenstein U, Delacher S et al. Distribution and antimicrobial activity of ciprofloxacin in human soft tissues. Antimicrob Agents Chemother1999; 43: 1307\u20139.","DOI":"10.1128\/AAC.43.5.1307"},{"key":"key\n\t\t\t\t20171010173126_B10","doi-asserted-by":"crossref","unstructured":"Sauermann R, Zeitlinger M, Erovic BM et al. Pharmacodynamics of piperacillin in severely ill patients evaluated by using a PK\/PD model. Int J Antimicrob Agents2003; 22: 574\u20138.","DOI":"10.1016\/j.ijantimicag.2003.05.003"},{"key":"key\n\t\t\t\t20171010173126_B11","unstructured":"Dalla Costa T, Nolting A, Rand K et al. Pharmacokinetic-pharmacodynamic modelling of the in vitro antiinfective effect of piperacillin-tazobactam combinations. Int J Clin Pharmacol Ther1997; 35: 426\u201333."},{"key":"key\n\t\t\t\t20171010173126_B12","doi-asserted-by":"crossref","unstructured":"Zeitlinger MA, Marsik C, Georgopoulos A et al. Target site bacterial killing of cefpirome and fosfomycin in critically ill patients. Int J Antimicrob Agents2003; 21: 562\u20137.","DOI":"10.1016\/S0924-8579(03)00047-5"},{"key":"key\n\t\t\t\t20171010173126_B13","doi-asserted-by":"crossref","unstructured":"Bone RC, Sibbald WJ, Sprung CL. The ACCP-SCCM consensus conference on sepsis and organ failure. Chest1992; 101: 1481\u20133.","DOI":"10.1378\/chest.101.6.1481"},{"key":"key\n\t\t\t\t20171010173126_B14","unstructured":"National Committee for Clinical Laboratory Standards. Performance Standards for Antimicrobial Susceptibility Testing; Fourteenth Informational Supplement M100-S14. NCCLS, Wayne, PA, USA, 2004."},{"key":"key\n\t\t\t\t20171010173126_B15","doi-asserted-by":"crossref","unstructured":"Joukhadar C, Klein N, Mayer BX et al. Plasma and tissue pharmacokinetics of cefpirome in patients with sepsis. Crit Care Med2002; 30: 1478\u201382.","DOI":"10.1097\/00003246-200207000-00013"},{"key":"key\n\t\t\t\t20171010173126_B16","doi-asserted-by":"crossref","unstructured":"Muller M, Brunner M, Hollenstein U et al. Penetration of ciprofloxacin into the interstitial space of inflamed foot lesions in non-insulin-dependent diabetes mellitus patients. Antimicrob Agents Chemother1999; 43: 2056\u20138.","DOI":"10.1128\/AAC.43.8.2056"},{"key":"key\n\t\t\t\t20171010173126_B17","unstructured":"National Committee for Clinical Laboratory Standards. Development of In Vitro Susceptibility Testing Criteria and Quality Control Parameters\u2014Second Edition: Approved Guideline M23-A2. NCCLS Wayne, PA, USA, 2001."},{"key":"key\n\t\t\t\t20171010173126_B18","doi-asserted-by":"crossref","unstructured":"Power BM, Forbes AM, van Heerden PV et al. Pharmacokinetics of drugs used in critically ill adults. Clin Pharmacokinet1998; 34: 25\u201356.","DOI":"10.2165\/00003088-199834010-00002"},{"key":"key\n\t\t\t\t20171010173126_B19","doi-asserted-by":"crossref","unstructured":"Craig WA. Pharmacokinetic\/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin Infect Dis1998; 26: 1\u201310; quiz 11\u201312.","DOI":"10.1086\/516284"},{"key":"key\n\t\t\t\t20171010173126_B20","doi-asserted-by":"crossref","unstructured":"Turnidge JD. The pharmacodynamics of \u03b2-lactams. Clin Infect Dis1998; 27: 10\u201322.","DOI":"10.1086\/514622"},{"key":"key\n\t\t\t\t20171010173126_B21","doi-asserted-by":"crossref","unstructured":"Kummerer K. Resistance in the environment. J Antimicrob Chemother2004; 54: 311\u201320.","DOI":"10.1093\/jac\/dkh325"},{"key":"key\n\t\t\t\t20171010173126_B22","doi-asserted-by":"crossref","unstructured":"Craig WA. Does the dose matter? Clin Infect Dis2001; 33 Suppl 3: S233\u20137.","DOI":"10.1086\/321854"},{"key":"key\n\t\t\t\t20171010173126_B23","doi-asserted-by":"crossref","unstructured":"Craig WA. Proof of concept: performance testing in models. Clin Microbiol Infect2004; 10 Suppl 2: 12\u201317.","DOI":"10.1111\/j.1470-9465.2004.00865.x"},{"key":"key\n\t\t\t\t20171010173126_B24","doi-asserted-by":"crossref","unstructured":"Lodise TP, Jr., Lomaestro B, Rodvold KA et al. Pharmacodynamic profiling of piperacillin in the presence of tazobactam in patients through the use of population pharmacokinetic models and Monte Carlo simulation. Antimicrob Agents Chemother2004; 48: 4718\u201324.","DOI":"10.1128\/AAC.48.12.4718-4724.2004"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jac\/article-pdf\/56\/4\/703\/2307909\/dki284.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,4,9]],"date-time":"2020-04-09T05:47:18Z","timestamp":1586411238000},"score":1,"resource":{"primary":{"URL":"http:\/\/academic.oup.com\/jac\/article\/56\/4\/703\/769308\/Plasma-concentrations-might-lead-to-overestimation"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,8,24]]},"references-count":24,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2005,8,24]]},"published-print":{"date-parts":[[2005,10,1]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dki284","relation":{},"ISSN":["1460-2091","0305-7453"],"issn-type":[{"value":"1460-2091","type":"electronic"},{"value":"0305-7453","type":"print"}],"subject":[],"published-other":{"date-parts":[[2005,10]]},"published":{"date-parts":[[2005,8,24]]}}}